3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
7227
Neoplasms
4535
Prostatic Neoplasms
3486
Colorectal Neoplasms
2930
Carcinoma, Non-Small-Cell Lung
2823
Lung Neoplasms
2539
Leukemia, Myeloid, Acute
1980
Pancreatic Neoplasms
1870
Multiple Myeloma
1805
Carcinoma, Hepatocellular
1729
Neoplasm Metastasis
1585
Stomach Neoplasms
1498
Lymphoma
1455
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1434
Head and Neck Neoplasms
1430
Brain Neoplasms
1367
Melanoma
1344
Ovarian Neoplasms
1339
Leukemia
1301
Rectal Neoplasms
1266
Recurrence
1249
Colonic Neoplasms
1204
Glioblastoma
1133
Uterine Cervical Neoplasms
1090
Lymphoma, Non-Hodgkin
1064
Leukemia, Lymphocytic, Chronic, B-Cell
989
Esophageal Neoplasms
963
Lymphoma, Follicular
936
Lymphoma, Large B-Cell, Diffuse
931
Squamous Cell Carcinoma of Head and Neck
920
Interventions
nilotinib
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Interventional
×
Substance Withdrawal Syndrome
×
Clear all
NCT04147533
2024-11-26
HALF
Masaryk University
Phase 2
Active not recruiting
150 enrolled